NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss ...

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

A few years ago, West Virginia, which has the highest obesity rate in the nation, quietly began a small and unusual pilot ...

These weight loss drugs are expensive out of pocket, though. Even with insurance, high co-pays can also limit who has access ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Indianapolis-based Lilly is testing its weight loss drug Zepbound to treat addiction, while Meta outages affected more than 150,000 users, and insurance company stocks have fallen since the murder of ...

Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.